Go to Top

Amicus Therapeutics to Present at 31st Annual J.P. Morgan Healthcare Conference

Amicus Therapeutics (FOLD) announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 9, 2013 at 3:00 p.m. PT.

Amicus Therapeutics (FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of human genetic diseases. Amicus’ late-stage programs for lysosomal storage disorders include migalastat HCl monotherapy in Phase 3 for Fabry disease; migalastat HCl co-administered with enzyme replacement therapy (ERT) in Phase 2 for Fabry disease; and AT2220 co-administered with ERT in Phase 2 for Pompe disease.